Golimumab is the fifth tumor necrosis factor (TNF) alpha inhibitor approved by the Food and Drug Administration for the treatment of rheumatoid arthritis. It is a fully humanized monoclonal antibody which exhibits high affinity for both transmembrane bound and soluble TNF. Based on data from the clinical trials, golimumab is only approved to be used in combination with methotrexate since golimumab monotherapy was not more efficacious than methotrexate monotherapy. Efficacy has been established in three patient populations: methotrexate naïve; methotrexate tolerant; and prior TNF alpha discontinuation. In all patient populations golimumab 50 mg subcutaneous injection every four weeks resulted in an improved patient response. The most common adverse effects are injection site reactions, nausea and liver enzyme increases. Golimumab also has two black box warnings for increased risk of infection and malignancy. Based on the limited indication and lack of long term data, golimumab should be reserved for patients who have failed other TNF alpha inhibitors.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
This is the most author-friendly process I have experienced. The staff were very attentive to us and kept us posted at every step of the process. They were great to work with. I commend the editorial staff for their professionalism and dedication to science and scientific publishing.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)